Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Common Equity (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Common Equity for 4 consecutive years, with -$438.2 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 72.79% to -$438.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$438.2 million through Dec 2025, down 72.79% year-over-year, with the annual reading at -$438.2 million for FY2025, 72.79% down from the prior year.
  • Common Equity for Q4 2025 was -$438.2 million at Phathom Pharmaceuticals, down from -$422.5 million in the prior quarter.
  • The five-year high for Common Equity was $38.0 million in Q1 2022, with the low at -$438.2 million in Q4 2025.
  • Average Common Equity over 4 years is -$166.3 million, with a median of -$119.3 million recorded in 2023.
  • The sharpest move saw Common Equity surged 351.43% in 2023, then tumbled 1428.57% in 2024.
  • Over 4 years, Common Equity stood at -$74.8 million in 2022, then rose by 2.75% to -$72.8 million in 2023, then plummeted by 248.52% to -$253.6 million in 2024, then crashed by 72.79% to -$438.2 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at -$438.2 million, -$422.5 million, and -$405.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.